RxDoctor Payments Data

Kimberly Sherrill

Family · Monroe, LANPI 1760452734

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 36 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$273
  • Ardelyx, Inc.$205
  • Fresenius USA Marketing, Inc.$180
  • Vifor Pharma, Inc.$107
  • Bayer$65
  • AstraZeneca$53
  • plus $152 from 8 others

What the payments were for

  • Food & beverage$1,01898%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 60th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$24,088
Medicare patients
81
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide94$208,763
AuryxiaFerric Citrate116$166,103
Lanthanum Carbonate25$18,473
Sevelamer Carbonate142$14,054
EntrestoSacubitril/Valsartan15$11,490
EliquisApixaban14$9,059
Clonidine20$1,987
Labetalol Hcl23$624
Nifedipine ErNifedipine33$541
Gabapentin29$326
Minoxidil12$284
Diltiazem 24hr ErDiltiazem Hcl12$261
Hydralazine Hcl13$244
Lidocaine-PrilocaineLidocaine/Prilocaine16$200
Carvedilol19$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$180$208,76394 claims
Akebia Therapeutics IncAuryxia$273$166,103116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,610 family providers in Louisiana.

Other family in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →